Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection: web annex 5: summary of available nonpangenotypic regimens

i Web Annex 5. Summary of available non- pangenotypic regimens In: Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection July 2018 ii WHO/CDS/HIV/18.39 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Web Annex 5. Summary of available non-pangenotypic regimens. In: Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.39). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication forms part of the WHO guideline entitled Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. It is being made publicly available as supplied by those responsible for its development for transparency purposes and information, as required by WHO (see the WHO handbook for guideline development, 2nd edition (2014)). iii Acknowledgement The World Health Organization (WHO) wishes to express its appreciation to the following individuals, who contributed to the development of this document: Marc Bulterys, Judith van Holten and Yvan Hutin, WHO, Geneva, Switzerland. 1 Summary table of available non-pangenotypic regimens Regimen Genotype coverage Can be used in persons with renal insufficiency Can be used in persons with de- compensated cirrhosis Propensity for drug-drug interactions Sofosbuvir/ Ledipasvir 1,4,5,6 NO NO Few Grazoprevir/ Elbasvir 1,4 YES NO Many Paritaprevir/ Ritonavir/ Ombitasvir + Dasabuvir 1 YES NO Many Simeprevir/ Sofosbuvir 1,4 NO NO Many